relatlimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies 5514 1673516-98-7

Description:

MoleculeDescription

Molfile

Synonyms:

  • relatlimab
  • relatlimab-rmbw
  • opdualag
  • BMS-986016
  • BMS986016
  • ONO-4482
Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 receptor, blocks interaction with its ligands, including MHC II, and reduces LAG-3 pathway-mediated inhibition of the immune response. Antagonism of this pathway promotes T cell proliferation and cytokine secretion. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human IgG4 monoclonal antibody that binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and reduces PD-1 pathwaymediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone. In murine syngeneic tumor models, LAG-3 blockade potentiates the anti-tumor activity of PD-1 blockage, inhibiting tumor growth and promoting tumor regression.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 15, 2022 EMA BRISTOL-MYERS SQUIBB PHARMA EEIG
March 18, 2022 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XY03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Combinations of antineoplastic agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000082082 Immune Checkpoint Inhibitors
FDA MoA N0000194002 Lymphocyte Activation Gene-3 Antagonists
FDA EPC N0000194003 Lymphocyte Activation Gene-3 Blocker

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Unresectable or metastatic melanoma indication 443493003
Advanced melanoma with tumour cell PD-L1 expression below 1% indication 443493003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Lymphocyte activation gene 3 protein Tumour-associated antigen ANTAGONIST Kd 9.92 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL3990044 ChEMBL_ID
C000721227 MESH_SUPPLEMENTAL_RECORD_UI
9536 IUPHAR_LIGAND_ID
DB14851 DRUGBANK_ID
018998 NDDF
4041299 VANDF
4041300 VANDF
C4724799 UMLSCUI
D11350 KEGG_DRUG
10735 INN_ID
2596772 RXNORM
357919 MMSL
40561 MMSL
d09869 MMSL
AF75XOF6W3 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OPDUALAG HUMAN PRESCRIPTION DRUG LABEL 2 0003-7125 INJECTION 4 mg INTRAVENOUS BLA 27 sections